A Wonder Drug in the Arsenal against COVID - 19: Medication Evidence from Ivermectin

Ivermectin, an FDA approved broad-spectrum anti-parasitic agent has been recently reported to show an inhibitory activity against SARS-CoV-2 in an in-vitro study. This antiviral response has rendered it as a potential drug to be repurposed for COVID-19. Previously, ivermectin had showed inhibitory activity against RNA viruses in-vitro and DNA viruses in-vitro and in-vivo respectively. Much of its characterization has been related to SARS-CoV wherein viral proteins interacting with IMPα/β1 (Importins) were proposed to enhance the viral infectivity. These documentations serve as a ray of hope for considering ivermectin in treating COVID-19 due to its suggested nuclear transport inhibitory mechanism. Importantly, these recent findings warrant detailed investigations for understanding its benefit in terms of efficacy and safety in COVID-19 patients. This review article throws light on the current consensus in this regard.